Oncolytics Biotech Inc.
ONCYHealthcare|Biotechnology|US
$0.44
-0.01 (-2.09%)
DCF Value
$0.02
Cash / Share
$0.03
Clinical Trials (23)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04215146 A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study | Breast Cancer Metastatic | P2 | Active | 48 | RCT, Open-label | Paclitaxel, Pelareorep, Avelumab |
| NCT04445844 INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study | Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Breast Carcinoma | P2 | Active | 25 | Open-label | Pelareorep, Retifanlimab |
| NCT07280377 A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab | Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified | P1P2 | Active | 122 | Open-label | Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel, Trifluridine Tipiracil, mFOLFIRINOX Treatment Regimen |
| NCT07446322 FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer | Ras-mutated Metastatic Colorectal Cancer, mCRC | P2 | Recruiting | 60 | RCT, Open-label | Bevacizumab, FOLFIRI, Pelareorep |
| NCT01166542 Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers | Carcinoma, Squamous Cell of the Head and Neck | P3 | Completed | 167 | RCT, Double-blind | REOLYSIN, Carboplatin, Paclitaxel, Placebo |
| NCT00984464 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma | Metastatic Melanoma | P2 | Completed | 14 | Open-label | REOLYSIN, Carboplatin, Paclitaxel |
| NCT01622543 Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer | Colorectal Cancer | P2 | Completed | 109 | RCT, Open-label | Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab |
| NCT00998322 A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | P2 | Completed | 34 | Open-label | REOLYSIN, Gemcitabine |
| NCT00861627 Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | Carcinoma, Non-small Cell Lung | P2 | Completed | 37 | Open-label | REOLYSIN®, Carboplatin, Paclitaxel |
| NCT01619813 Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | Prostate Cancer | P2 | Completed | 85 | RCT, Open-label | Docetaxel, Reolysin and Prednisone, Docetaxel and Prednisone |
| NCT01708993 Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy | Non Small Cell Lung Cancer | P2 | Completed | 166 | RCT, Open-label | Pemetrexed and Reolysin (and safety run-in), Pemetrexed, Docetaxel and Reolysin, Docetaxel |
| NCT00503295 Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung | Osteosarcoma, Ewing Sarcoma Family Tumors | P2 | Completed | 53 | Open-label | REOLYSIN® |
| NCT00753038 Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma | Carcinoma, Squamous Cell of the Head and Neck | P2 | Completed | 14 | Open-label | REOLYSIN®, Carboplatin, Paclitaxel |
| NCT01656538 A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer | Metastatic Breast Cancer | P2 | Completed | 81 | RCT, Open-label | Paclitaxel, Reolysin |
| NCT00998192 A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung | Metastatic or Recurrent Squamous Cell Carcinoma of the Lung | P2 | Completed | 32 | Open-label | REOLYSIN, Paclitaxel, Carboplatin |
| NCT01274624 Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer | KRAS Mutant Metastatic Colorectal Cancer | P1 | Completed | 36 | Open-label | REOLYSIN®, Irinotecan, Leucovorin, Fluorouracil (5-FU), Bevacizumab |
| NCT02723838 Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder | Muscle-invasive Transitional Cell Carcinoma of the Bladder | P1 | Withdrawn | — | Open-label | REOLYSIN®, Gemcitabine, Cisplatin |
| NCT00528684 Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas | Malignant Glioma | P1 | Completed | 18 | Open-label | REOLYSIN® |
| NCT02620423 Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | P1 | Completed | 11 | Open-label | REOLYSIN®, Chemotherapy, Gemcitabine, Irinotecan, Leucovorin, 5-fluorouracil, Pembrolizumab |
| NCT02514382 Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | P1 | Completed | 14 | Open-label | Bortezomib, Dexamethasone, Wild-type Reovirus |
| NCT03015922 Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma | Multiple Myeloma | P1 | Unknown | 4 | Open-label | Lenalidomide or Pomalidomide, REOLYSIN |
| NCT03605719 Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma | Recurrent Plasma Cell Myeloma | P1 | Completed | 23 | Open-label | Carfilzomib, Dexamethasone, Nivolumab, Pelareorep |
| NCT04102618 A Window-of-opportunity Study of Pelareorep in Early Breast Cancer | Breast Cancer | Early P1 | Terminated | 26 | Open-label | Pelareorep, Letrozole, Atezolizumab, Trastuzumab |